The associations found in the current study may provide the basis for the design of future trials to proactively re-design and optimize care modalities for the HF and other vulnerable patient populations, such as those with severe chronic obstructive pulmonary disease, cancer, diabetes mellitus on insulin-pump, among others. This evidence concerns the gene INS and chronic obstructive pulmonary disease.